Effectiveness and safety of the conversion to MeltDose® extended‐release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study

Tacrolimus is the cornerstone of immunosuppressive therapy after kidney transplantation. Its narrow therapeutic window mandates serum level strict monitoring and dose adjustments to ensure the optimal risk‐benefit balance. This observational retrospective study analyzed the effectiveness and safety...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical transplantation 2020-01, Vol.34 (1), p.e13767-n/a
Hauptverfasser:	Sánchez Fructuoso, Ana, Ruiz, Juan Carlos, Franco, Antonio, Diekmann, Fritz, Redondo, Dolores, Calviño, Jesús, Serra, Nuria, Aladrén, María José, Cigarrán, Secundino, Manonelles, Ana, Ramos, Ana, Gómez, Gonzalo, González Posada, José Manuel, Andrés, Amado, Beneyto, Isabel, Muñiz, Andrés López, Perelló, Manel, Lauzurica, Ricardo
Format:	Artikel
Sprache:	eng
Schlagworte:	extended‐release tacrolimus immediate‐release tacrolimus kidney transplant LCPT Original prolonged‐release tacrolimus tacrolimus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Tacrolimus is the cornerstone of immunosuppressive therapy after kidney transplantation. Its narrow therapeutic window mandates serum level strict monitoring and dose adjustments to ensure the optimal risk‐benefit balance. This observational retrospective study analyzed the effectiveness and safety of conversion from twice‐daily immediate‐release tacrolimus (IR‐Tac) or once‐daily prolonged‐release tacrolimus (PR‐Tac) to the recent formulation once‐daily MeltDose® extended‐release tacrolimus (LCP‐Tac) in 365 stable kidney transplant recipients. We compared kidney function three months before and three months after the conversion. Three months after conversion, the total daily dose was reduced ~35% (P
ISSN:	0902-0063 1399-0012
DOI:	10.1111/ctr.13767